Sarepta Therapeutics (SRPT) Q2 2026 earnings review
ELEVIDYS Collapse Continues Amid Leadership Transition
Sarepta's Q2 2026 results expose the ongoing failure of its ELEVIDYS commercial 'reset.' ELEVIDYS revenue plummeted for the fourth consecutive quarter to just $98.1M, a stark contrast to the $282M peak a year ago. Management quietly narrowed full-year product revenue guidance to the lower end ($1.2B-$1.3B), effectively abandoning the previously touted '$500M floor' for the gene therapy. The only bright spot is profitability: ruthless 2025 cost cuts slashed operating expenses, preserving $86.5M in Non-GAAP operating income and protecting a $945M cash pile. Newly appointed CEO Michael Severino steps into a challenging environment, tasked with reviving the core growth engine while shepherding the unproven siRNA pipeline toward critical H2 data readouts.
🐂 Bull Case
The massive 36% headcount reduction from Q2 2025 continues to pay dividends. Non-GAAP operating expenses (R&D + SG&A) dropped dramatically YoY, allowing Sarepta to post strong Non-GAAP profitability despite an evaporating top-line.
The legacy PMO franchise generated $230.6M, providing a stable, highly-compliant baseline of cash flow. With sNDAs accepted for traditional approval of AMONDYS and VYONDYS, the regulatory tail risk is diminishing.
🐻 Bear Case
Management previously stress-tested ELEVIDYS at a '$500 million floor' for 2026. With only $200.1M generated in H1, they would need a miraculous 50% sequential jump in H2 to hit that floor—a scenario contradicted by their own lowered revenue guidance.
Doug Ingram's departure comes at the worst possible time for ELEVIDYS. New CEO Michael Severino must attempt to bridge the 'massive information gap' with physicians while simultaneously navigating critical siRNA data readouts.
⚖️ Verdict: 🔴
Bearish. Sarepta has successfully transformed into a cash-flow-positive entity through severe austerity, but a biotech cannot cut its way to long-term growth. The relentless quarterly decline of ELEVIDYS indicates severe, persistent physician hesitancy that commercial initiatives are failing to resolve.
Key Themes
ELEVIDYS Turnaround Fails to Materialize
The 'long-cycle' commercial initiatives touted heavily in Q4 2025 and Q1 2026 have yet to show up in the numbers. Q2 ELEVIDYS revenue fell to $98.1M, a 65% drop from its $282M peak in Q2 2025 prior to the FDA-mandated label restriction. The continuous sequential deterioration proves that physician education efforts and the expanded sales force have not yet overcome the safety-related hesitancy created last year.
Aggressive Austerity Preserves the Balance Sheet
Sarepta's decision to cut 36% of its workforce and deprioritize its limb-girdle pipeline in 2025 is the singular reason the company remains financially viable today. Combined Non-GAAP R&D and SG&A dropped 44% YoY in Q2 to $164.7M. This radical cost containment allowed Sarepta to post $86.5M in Non-GAAP operating income, fully shielding its $945M cash pile from operational burn.
Sudden Litigation Charge Sinks GAAP Profits
The company recorded an unexpected $39.0 million litigation contingency charge related to the potential resolution of patent litigations. Management deemed a loss 'probable and estimable'. This one-time hit was severe enough to pull Q2 GAAP operating income down to just $13.3M and drag GAAP net income into negative territory (-$4.9M). It highlights lingering IP risks hanging over the commercial portfolio.
Pivoting the Narrative to siRNA
With ELEVIDYS struggling, management is shifting investor focus to its Arrowhead-partnered siRNA platform. The company confirmed that readouts from the Multiple Ascending Dose (MAD) cohorts for SRP-1001 (FSHD) and SRP-1003 (DM1) are on track for H2 2026. Because these indications represent massive, untreated patient populations, the clinical validation of Sarepta's proprietary integrin-targeting ligand is now the company's most critical value-creation catalyst.
Leadership Transition Accelerates
The CEO succession announced emotionally in Q4 2025 is now complete. Michael Severino, MD, officially took over on July 28, 2026, succeeding Doug Ingram. Severino brings significant large-pharma pedigree (AbbVie, Amgen), which is exactly what Sarepta needs to commercialize its pipeline globally. However, switching leadership while the core product is actively shrinking injects a high degree of execution risk into the next 12 months.
Other KPIs
Stable. The foundation of Sarepta's business (EXONDYS, VYONDYS, AMONDYS) held flat sequentially (vs $228.6M in 26Q1). Despite past clinical trial misses, the franchise continues to generate roughly $900M annualized, proving high patient compliance and serving as the financial bedrock while ELEVIDYS falters.
Stable. Down insignificantly from $953.8M at the end of 2025. The company's cost-cutting measures have successfully insulated the balance sheet from the ELEVIDYS revenue drop, keeping Sarepta well-capitalized to advance its siRNA trials without needing dilutive equity raises.
Guidance
Decelerating. Management narrowed the guidance downward from the previous $1.2B-$1.4B range. With $659.2M already booked in H1 2026, the $1.25B midpoint implies H2 2026 revenue of just $590.8M. This means management actually expects the back half of the year to be worse than the first half, completely dispelling the 'H2 commercial inflection' narrative touted in prior calls.
Stable. Narrowed from $800M-$900M. This tightening confirms that Sarepta is adhering strictly to its austere post-restructuring budget and has no intention of spending its way out of the current commercial rut.
Key Questions
The Implied H2 Deceleration
Your narrowed FY26 guidance implies that H2 total net product revenue will be lower than H1. If the 'massive information gap' is being addressed by your expanded sales force, why are you modeling a half-over-half contraction rather than an inflection?
ELEVIDYS Non-Ambulatory Pathway
You expect full enrollment of ENDEAVOR Cohort 8 by year-end and data in Q1 2027. Assuming the sirolimus pretreatment data is positive, what is your assumed timeline for negotiating a label expansion with the FDA to return to the non-ambulatory market?
Litigation Settlement Dynamics
Regarding the $39 million litigation contingency charge, does this prospective settlement encompass all outstanding patent disputes, and will it result in any ongoing royalty burdens on the PMO franchise?